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In normal blood vessels, heparan sulfate proteoglycan on the surface of endothelial
cells functions to maintain an anticoagulant environment by localized activation of
antithrombin III (1, 2), a potent inhibitor of thrombin generation. Heparan sulfate
proteoglycan also renders endothelial surfaces relatively impermeable to transit of
blood cells and plasma proteins (3, 4). Intravascular coagulation and extravasation
of blood elements are prominent pathological features of hyperacute rejection (5)
and otherdiseases thought to be mediated by the binding of antibodies to endothelium
and the consequent activation of complement. We therefore used an in vitro model
to test the hypothesis that binding of human natural antibodies to xenogeneic en-
dothelium might lead to a change in cell-associated proteoglycan, which in turn might




Serum samples from normal individuals were pooled or used individually.
Antibody reactivitywith cultured porcine endothelial cells was assayed by ELISA(12). Serum
was obtained from two individuals deficient of C2 (13) and pooled serum from which Factor
B had been immunoabsorbed was obtained from Cytotech (San Diego, CA). The natural
antibody titers ofcomplement-deficient sera were comparable to those ofnormal human sera.
Porcine serum had no reactivity and one human serum had very markedly decreased reac-
tivity with cultured endothelial cells (12). Purified C2 (Cordis) used at 2,000 U/ml recon-
stituted C2-deficient serum to low normal complement activity (CH50).
Endothelial Cell Cultures, Biosynthetic Labeling, and Extraction ofProteoglycans.
￿
Porcine aortic
endothelial cells were cultured in DME with 20% vol/vol heat-inactivated FCS and antibi-
otics (14). Endothelial cell identity was based on the ability to take up acetylated low density
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lipoprotein (15). Cell monolayers were labeled with [35S]sulfate (100 ttCi/ml) in DME (0 .124
t.M sulfate) for 16 h, washed, then incubated at 37°C in RPMI 1640 containing 25% vol/vol
pooled fresh human serum. The supernatant was saved and the cell fractions were then ex-
tracted with 4 M guanidine HCl, 0.05 M sodium acetate, 0.01 M EDTA, 0 .1 M 6-amino-
hexanoic acid, 0.5 mg/ml 1,10-phenanthroline, 1 mg/ml benzamidine, 1 mM iodoacetamide,
pH 5.8, at 4°C for 24 h. Extracts and supernatant fractions were exhaustively dialyzed in
3,500 dalton exclusion tubing against 0.5 M sodium acetate, 0.1 M sodium sulfate, 0.01 M
EDTA, 0.1 M 6-aminohexanoic acid, and 10 mM PMSF. Percent proteoglycan release was
determined as: 100 x [(cpm medium)/(cpm medium + cpm cells)].
For determination of "Cr release, endothelial cell monolayers in 2-cm' wells were washed
with RPMI 1640 and then labeled with "Cr (2 ACi/well) for 2-3 h at 37°C. Cells were then
washed with RPMI 1640 and incubated in human serum as described above. The superna-
tant fraction (A) was removed, cells (B) were extracted with 1 N NaOH, and the radioactivity
was counted. The control cells were incubated in RPMI alone and supernatants (C) were
counted. Percent cytotoxicity was determined as: 100 x [(A - C)/(A + B - C)]. Values
shown represent the mean of four determinations. In some experiments, endothelial cells
were exposed to human serum for 1 h, washed, and then incubated in [3H]thymidine
(1pCi/ml) or [3H]uridine (41Ci/ml) for 16 h. Cell fractions were then washed and extracted
as described above.
Characterization ofEndothelial Cell Proteoglycans.
￿
Porcine endothelial cell extracts and super-
natant fractions prepared as described abovewere dialyzed into 6 M urea, 0.1 M NaCl, 0.05
M Tris,0 .2% CHAPS with protease inhibitors, pH 7.0, applied to DEAF-Sephacel columns
and eluted with a 0.1 M NaCl to 2.0 M NaCl gradient in the same buffer (14). Fractions
representing eluted peaks were pooled and applied to a 100 cm x 0.6 cm Sepharose CL-4B
column, equilibrated, and eluted with 4 M guanidine HCl in 0.05 M NaAc (Vo 19.6 ml;
V 49 ml). Samples were also studied by electrophoresis in 0.6% agarose-1.6% polyacryl-
amide gels from which fluorograms were prepared (16). Samples of cell and supernatant frac-
tions were digested with heparitinase or with chondroitinase ABC in the presence of protease
inhibitors (17) before electrophoresis.
Results and Discussion
Exposure of porcine endothelial cells to human serum caused release of -5% of
labeled proteoglycans at 4 min and >50% at 1 h (Fig. 1). Loss of heparan sulfate
proteoglycan from endothelial cells at these times did not reflect irreversible changes
leading to cell death as endothelial cells prelabeled with "Cr and then exposed to
fresh human serum released proteoglycan before any detectable release of "Cr-
labeled material (Fig. 1) . Further, endothelial cells exposed to fresh human serum
for 1 h and then washed and placed back in culture incorporated the same amounts
of [3H]uridine (246, 225 cpm) and [3H]thymidine (10,067 cpm) during a subsequent
16-h period, as did controls [3H]uridine (255,568 cpm), [3H]thymidine (11,125 cpm).
After continued exposure of endothelial cells to human serum for 4 h, release of
S 'Cr was observed (Fig. 1), and incorporation of [ 3H]thymidine decreased (data not
shown).
Purification and analysis of endothelial cell proteoglycans after treatment of cul-
tured cellswith human serum for 1 h revealed that the smaller of two heparan sulfate
proteoglycans normally associated with porcine endothelial cells (2, 18, 19) was no
longer present (Fig. 2). The supernatant contained fragments of this proteoglycan
that, based on elution from molecular sieve columns and electrophoretic migration,
consisted of glycopeptides or glycosaminoglycan chains. The released proteoglycan
and fragments were shown to be heparan sulfate, as they were sensitive to digestion











Release of [35S]sulfate-labeled pro-
teoglycans and "Crfrom cultured porcine aortic
endothelial cellsexposed to humannatural anti-
bodies and complement in human serum.
suggest that release is mediated by enzymatic cleavage of the protein core and/or
of glycosaminoglycan chains. In contrast, supernatant from endothelial cellsexposed
to human serum for 4 h contained intact proteoglycan, possibly reflecting vesicula-
tion or cell lysis as well as proteoglycan fragments (Fig. 2 D).
The cleavage and release of endothelial cell proteoglycans appeared to be trig-
gered by the bindingofnatural antibodies to endothelial cells andactivation ofcom-
plement. Proteoglycan release was observed with pooled human sera (Fig. 1) and
with sera obtained from individuals manifesting natural antibody reactivity with
porcine endothelial cells. In contrast, serum from one individual with a very low
natural antibody titerdid not cause proteoglycan release (Table I). That the critical
component lackingin this serum in termsof itsinability to mediatereleaseofheparan
sulfate is the absence of the natural antibodies is evidenced by the ability of that
serum to mediate release from endothelial cells precoated with natural antibodies
(Table I). In addition, porcine serum that contained no detectable anti-porcine en-
dothelial antibodies caused no release.
The role of complement activation was evaluated by exposing cultured porcine
endothelial cellsto human sera deficient in complement (Table I). Heat-inactivated
human serum or human sera deficient in C2 did not cause release of labeled pro-
teoglycans. Repletion of theC2-deficient serumwith purified C2 to low normal com-
plement activity enabled that serum to mediate proteoglycan release comparable
to that seen for normal individuals. Factor B-depleted serum didcause proteoglycan
release. These results indicated that cleavage andreleaseofendothelial proteoglycans
depended upon activation of the classical complement pathway.
The loss of heparan sulfate proteoglycan from endothelial cells mediated by nat-
ural antibodies and complement may induce a series of events that could well con- .
tribute in a major way to two of the key features of hyperacute rejection: interstitial
hemorrhage and intravascular thrombosis. It seems reasonable to suggest that the
same mechanism, i.e., loss of heparan sulfateproteoglycan, maybe involved in other
diseases such as hemolytic uremic syndrome or Kawasaki disease, which may be
mediated by anti-endothelial cell antibodies (20, 21). The presence of heparan sul-1366
￿
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FIGURE 2 .
￿
Analysis by gel filtration chromatography and gel
electrophoresis of [31S]sulfate-labeled porcine endothelial cell
proteoglycans after treatment ofmonolayers with humanserum .
(A)Proteoglycans from porcine aortic endothelial cells, exposed
to heat-inactivated (56°C, 30 min)humanserum, eluted from
Sepharose CL-4B columns as overlapping peaks denoted a (K-
0.04) and b (K., 0.35) . Sensitivity of corresponding elec-
trophoretic bands to heparitinase (designated +) is shown . (B)
Proteoglycans from endothelial cells exposed to fresh human
serumwere in peak/band a and in aminor, late eluting peak/
band c (K., 0.73), whereas peak/band b was absent. (C Su-
pernatant of endothelial cells briefly exposed (15min) to human
serumcontained molecules in the form ofglycopeptides and/or
glycosaminoglycans (peak/band c) sensitive to digestion by
heparitinase. (D) Supernatant from monolayers exposed to
human serum for 4 hcontained proteoglycan fragments as in
C and larger, apparently intact proteoglycans (peaks a-c) .
TABLE I
Role of the Classical Pathway in Release of Proteoglycansfrom Cultured






27-57 (x = 43.2)
2 .1-3 .8 (x = 2.9)
" The percent release of [35S]sulfate-labeled proteoglycans from cultured por-
cine endothelial cells was determined after incubation of labeled endothelial
cells with medium containing25% serum for 60 minas described in Materi-
alsand Methods . In oneexperiment, endothelial cells were incubated in nor-
mal heat-inactivated serum (which by itselfcaused no release at 60 or 120 min),
washed, and then incubated with natural antibody-deficient serum 1 . C2 alone
caused no release .
Natural antibody deficient serum #1 7 .1
Normal heat-inactivated serum +
natural antibody-deficient serum #1 45.0
C2-deficient serum 1 3.5
C2-deficient serum 2 12 .7
C2-deficient serum 2 + purified C2 30 .7
Factor B-depleted serum 49.4





fate proteoglycan on endothelial cell surfaces is involved in binding of extracellular
superoxide dismutase (22, 23), which protects against injury by oxygen radicals (24).
The loss of heparan sulfate proteoglycan from the endothelial cells might render
the cells subject to oxidant-mediated cell injury, as occurs in organ preservation (re-
perfusion) injury. The understanding of the mechanisms leading to loss of heparan
sulfate proteoglycan may allow the devising of strategies to prevent the sequelae of
that loss.
Summary
Heparan sulfate proteoglycan associated with endothelial cells in normal blood
vessels inhibits intravascular coagulation and egress of blood cells and plasma pro-
teins, key features ofhyperacute rejection. It was shown herein that exposure of cul-
tured porcine endothelium to human serum as a source of natural antibodies and
complement caused cleavage and release of5 % ofendothelial cell proteoglycans within
4 min and >50% within 1 h. Proteoglycan release depended on activation of the
classical complement pathway and preceded irreversible cell injury. These findings
suggest that loss of endothelial cell proteoglycan may be a critical step in the patho-
genesis ofhyperacute rejection and in diseases involvinghumoral injury to endothelial
cells.
We thank Nathan Ihrke and Kim Butters for expert technical assistance and Connie Green-
berg for manuscript preparation.
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